Article Contents ::

Details About Generic Salt ::  Sirolimu

Main Medicine Class:: Immunosuppressive   

(SER-oh-lih-muss)
Rapamune
Solution, oral: 1 mg/mL
Class: Immunosuppressive

 Indications Prophylaxis of organ rejection in patients receiving renal transplants.

Treatment of psoriasis.

 Contraindications Standard considerations.

 Route/Dosage

Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus.

ADULTS: PO Recommended loading dose of 6 mg with a daily maintenance dose of 2 mg (ie, loading dose 3 times the maintenance dose) in a regimen with cyclosporine and corticosteroids.

ADULTS AND CHILDREN at least 13 yr who weigh less than 40 kg: PO Adjust dose to 1 mg/m2/day based on body surface area. The loading dose should be 3 mg/m2.

Hepatic Impairment: PO Reduce maintenance dose by approximately 33%; do not modify loading dose.

 Interactions

Cyclosporine: Sirolimus plasma concentrations may be increased; administer sirolimus 4 hr after cyclosporine. Cytochrome P450 3A4 inhibitors (eg, erythromycin, protease inhibitors [eg, ritonavir], verapamil): Sirolimus plasma levels may be elevated, increasing the pharmacologic and adverse effects. Cytochrome P450 3A4 inducers (eg, carbamazepine, phenytoin, St. John’s wort): Sirolimus plasma levels may be reduced, decreasing the pharmacologic effects. Diltiazem, ketoconazole: Sirolimus plasma concentrations may be increased. Rifampin: Sirolimus plasma concentrations may be decreased. Vaccination: Response to vaccination may be less effective.

 Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Hypertension; hypotension; atrial fibrillation; CHF; hemorrhage; hypervolemia; palpitations; peripheral vascular disorder; postural hypotension; syncope; tachycardia; thrombophlebitis; thrombosis; vasodilation. CNS: Insomnia; tremor; headache; anxiety; confusion; depression; dizziness; emotional lability; hypertonia; hyperesthesia; hypotonia; neuropathy; paresthesia; somnolence. DERMATOLOGIC: Acne; rash; skin ulcer; fungal dermatitis; hirsutism; pruritus; skin hypertrophy; sweating. EENT: Abnormal vision; cataract; conjunctivitis; deafness; ear pain; otitis media; tinnitus. GI: Constipation; diarrhea; dyspepsia; nausea; vomiting; anorexia; dysphagia; eructation; esophagitis; flatulence; gastritis; gastroenteritis; gingivitis; gum hyperplasia; ileus; mouth ulceration; oral moniliasis; stomatitis. GU: UTI; albuminuria; bladder pain; dysuria; hematuria; hydronephrosis; impotence; kidney pain; kidney tubular necrosis; nocturia; oliguria; pyuria; scrotal edema; testis disorder; toxic nephropathy; increased urinary frequency; urinary incontinence; urinary retention. HEMATOLOGIC: Anemia; leukopenia; thrombocytopenia; ecchymosis; leukocytosis; lymphadenopathy; polycythemia. HEPATIC: Abnormal LFTs. METABOLIC: Increased serum creatinine; hypercholesterolemia; hyperkalemia; hyperlipemia; hypokalemia; increased LDH; hypophosphatemia; weight gain/loss; diabetes mellitus; glucosuria; acidosis; increased alkaline phosphatase; increased BUN; increased creatine phosphokinase; dehydration; abnormal healing; hypercalcemia; hypoglycemia; hypomagnesemia; hyponatremia. RESPIRATORY: Dyspnea; pharyngitis; upper respiratory tract infection; asthma; atelectasis; bronchitis; increased cough; epistaxis; hypoxia; lung edema; pleural effusion; pneumonia; rhinitis; sinusitis. OTHER: Edema; peripheral edema; abdominal pain; asthenia; back pain; chest pain; fever; pain; arthralgia; lymphocele; facial edema; Cushing syndrome; arthrosis; bone necrosis; leg cramps; myalgia; osteoporosis; tetany; abdominal enlargement; abscess; ascites; cellulitis; chills; flu syndrome; hernia; infection; malaise; pelvic pain; peritonitis; sepsis.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children younger than 13 yr: Safety and efficacy not established. Infection: Increased susceptibility to infection, including Pneumocystis carinii may occur. Lipids: Increased serum cholesterol and triglycerides, requiring treatment, may occur. Lymphoma: Increased possibility of developing lymphoma. Renal function: Decreased renal function may occur; monitor closely.

PATIENT CARE CONSIDERATIONS


 Administration/Storage

  • Refrigerate and protect from light oral solution bottles and pouches at 2° to 8°C (36° to 46°F). They will be stable for 24 mo.
  • Once the contents are opened, use within a short period of time. Review package inserts for specific instructions. If a slight haze appears, shake gently until the haze disappears.
  • Anticipate administration in a regimen with cyclosporine and corticosteroids for prevention of renal rejection.
  • Administer 4 hr after cyclosporine.
  • Administer diluted as directed.
  • Do not administer with grapefruit juice or use grapefruit juice for dilution.

 Assessment/Interventions

  • Obtain patient history including drug history and any known allergies.
  • Manage patients receiving sirolimus in facilities equipped and staffed with adequate laboratory and supportive medical resources.
  • Monitor patient for potential drug interactions and side effects.
  • Monitor blood sirolimus levels in pediatric patients, patients with hepatic function impairment, or during coadministration of strong CYP3A4 inducers and inhibitors, and if cyclosporine dosage is markedly reduced or discontinued.
  • Monitor patient for signs and symtoms of graft rejection including increased fever, pain over transplant site, weight gain, and increased serum creatinine.
  • Monitor patient for signs and symptoms of infection, bleeding, bruising, or development of lymphoma.
OVERDOSAGE: SIGNS & SYMPTOMS
  Atrial fibrillation

 Patient/Family Education

  • Inform patient of the risks and benefits of sirolimus therapy.
  • Give patients complete dosage instructions and review the product information with the patient.
  • Instruct patient concerning signs and symptoms of renal rejection and to report them immediately to health care provider.
  • Instruct patient to inform the health care provider immediately if experiencing signs and symptoms of infection.
  • Caution women of childbearing potential to use effective contraception prior to the initiation of sirolimus therapy, during, and for 12 wk after therapy has been discontinued.
  • Instruct patient to take medication consistently with or without food.
  • Warn patient not to alter the dose or discontinue the medication without consulting the health care provider.
  • Instruct patient to check with health care provider before taking any OTC or prescription medication, or receiving any vaccination.
  • Caution patient to inform the health care provider if pregnant, planning to become pregnant, or planning to breastfeed.

 

Drugs Class ::

(SER-oh-lih-muss)
Rapamune
Solution, oral: 1 mg/mL
Class: Immunosuppressive

Indications for Drugs ::

 Indications Prophylaxis of organ rejection in patients receiving renal transplants.

Treatment of psoriasis.

Drug Dose ::

 Route/Dosage

Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use sirolimus.

ADULTS: PO Recommended loading dose of 6 mg with a daily maintenance dose of 2 mg (ie, loading dose 3 times the maintenance dose) in a regimen with cyclosporine and corticosteroids.

ADULTS AND CHILDREN at least 13 yr who weigh less than 40 kg: PO Adjust dose to 1 mg/m2/day based on body surface area. The loading dose should be 3 mg/m2.

Hepatic Impairment: PO Reduce maintenance dose by approximately 33%; do not modify loading dose.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children younger than 13 yr: Safety and efficacy not established. Infection: Increased susceptibility to infection, including Pneumocystis carinii may occur. Lipids: Increased serum cholesterol and triglycerides, requiring treatment, may occur. Lymphoma: Increased possibility of developing lymphoma. Renal function: Decreased renal function may occur; monitor closely.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Hypertension; hypotension; atrial fibrillation; CHF; hemorrhage; hypervolemia; palpitations; peripheral vascular disorder; postural hypotension; syncope; tachycardia; thrombophlebitis; thrombosis; vasodilation. CNS: Insomnia; tremor; headache; anxiety; confusion; depression; dizziness; emotional lability; hypertonia; hyperesthesia; hypotonia; neuropathy; paresthesia; somnolence. DERMATOLOGIC: Acne; rash; skin ulcer; fungal dermatitis; hirsutism; pruritus; skin hypertrophy; sweating. EENT: Abnormal vision; cataract; conjunctivitis; deafness; ear pain; otitis media; tinnitus. GI: Constipation; diarrhea; dyspepsia; nausea; vomiting; anorexia; dysphagia; eructation; esophagitis; flatulence; gastritis; gastroenteritis; gingivitis; gum hyperplasia; ileus; mouth ulceration; oral moniliasis; stomatitis. GU: UTI; albuminuria; bladder pain; dysuria; hematuria; hydronephrosis; impotence; kidney pain; kidney tubular necrosis; nocturia; oliguria; pyuria; scrotal edema; testis disorder; toxic nephropathy; increased urinary frequency; urinary incontinence; urinary retention. HEMATOLOGIC: Anemia; leukopenia; thrombocytopenia; ecchymosis; leukocytosis; lymphadenopathy; polycythemia. HEPATIC: Abnormal LFTs. METABOLIC: Increased serum creatinine; hypercholesterolemia; hyperkalemia; hyperlipemia; hypokalemia; increased LDH; hypophosphatemia; weight gain/loss; diabetes mellitus; glucosuria; acidosis; increased alkaline phosphatase; increased BUN; increased creatine phosphokinase; dehydration; abnormal healing; hypercalcemia; hypoglycemia; hypomagnesemia; hyponatremia. RESPIRATORY: Dyspnea; pharyngitis; upper respiratory tract infection; asthma; atelectasis; bronchitis; increased cough; epistaxis; hypoxia; lung edema; pleural effusion; pneumonia; rhinitis; sinusitis. OTHER: Edema; peripheral edema; abdominal pain; asthenia; back pain; chest pain; fever; pain; arthralgia; lymphocele; facial edema; Cushing syndrome; arthrosis; bone necrosis; leg cramps; myalgia; osteoporosis; tetany; abdominal enlargement; abscess; ascites; cellulitis; chills; flu syndrome; hernia; infection; malaise; pelvic pain; peritonitis; sepsis.

Drug Mode of Action ::  

(SER-oh-lih-muss)
Rapamune
Solution, oral: 1 mg/mL
Class: Immunosuppressive

Drug Interactions ::

 Interactions

Cyclosporine: Sirolimus plasma concentrations may be increased; administer sirolimus 4 hr after cyclosporine. Cytochrome P450 3A4 inhibitors (eg, erythromycin, protease inhibitors [eg, ritonavir], verapamil): Sirolimus plasma levels may be elevated, increasing the pharmacologic and adverse effects. Cytochrome P450 3A4 inducers (eg, carbamazepine, phenytoin, St. John’s wort): Sirolimus plasma levels may be reduced, decreasing the pharmacologic effects. Diltiazem, ketoconazole: Sirolimus plasma concentrations may be increased. Rifampin: Sirolimus plasma concentrations may be decreased. Vaccination: Response to vaccination may be less effective.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history including drug history and any known allergies.
  • Manage patients receiving sirolimus in facilities equipped and staffed with adequate laboratory and supportive medical resources.
  • Monitor patient for potential drug interactions and side effects.
  • Monitor blood sirolimus levels in pediatric patients, patients with hepatic function impairment, or during coadministration of strong CYP3A4 inducers and inhibitors, and if cyclosporine dosage is markedly reduced or discontinued.
  • Monitor patient for signs and symtoms of graft rejection including increased fever, pain over transplant site, weight gain, and increased serum creatinine.
  • Monitor patient for signs and symptoms of infection, bleeding, bruising, or development of lymphoma.
OVERDOSAGE: SIGNS & SYMPTOMS
  Atrial fibrillation

Drug Storage/Management ::

 Administration/Storage

  • Refrigerate and protect from light oral solution bottles and pouches at 2° to 8°C (36° to 46°F). They will be stable for 24 mo.
  • Once the contents are opened, use within a short period of time. Review package inserts for specific instructions. If a slight haze appears, shake gently until the haze disappears.
  • Anticipate administration in a regimen with cyclosporine and corticosteroids for prevention of renal rejection.
  • Administer 4 hr after cyclosporine.
  • Administer diluted as directed.
  • Do not administer with grapefruit juice or use grapefruit juice for dilution.

Drug Notes ::

 Patient/Family Education

  • Inform patient of the risks and benefits of sirolimus therapy.
  • Give patients complete dosage instructions and review the product information with the patient.
  • Instruct patient concerning signs and symptoms of renal rejection and to report them immediately to health care provider.
  • Instruct patient to inform the health care provider immediately if experiencing signs and symptoms of infection.
  • Caution women of childbearing potential to use effective contraception prior to the initiation of sirolimus therapy, during, and for 12 wk after therapy has been discontinued.
  • Instruct patient to take medication consistently with or without food.
  • Warn patient not to alter the dose or discontinue the medication without consulting the health care provider.
  • Instruct patient to check with health care provider before taking any OTC or prescription medication, or receiving any vaccination.
  • Caution patient to inform the health care provider if pregnant, planning to become pregnant, or planning to breastfeed.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.